Related Experiment Video
Updated: Apr 5, 2026
06:27
Transcutaneous Microcirculatory Imaging in Preterm Neonates
Published on: December 31, 2015
8.6K
Darbepoetin Administration in Term and Preterm Neonates
1Division of Neonatology, Department of Pediatrics, University of Utah, 296 Chipeta Way, Salt Lake City, UT 84105, USA.
Clinics in Perinatology
|August 8, 2015
Summary
Erythropoiesis-stimulating agents (ESAs) show promise for preterm and term infants, offering red blood cell growth and potential neuroprotection. Clinical trials indicate ESAs can reduce transfusions and prevent brain injury.
Area of Science:
- Neonatal Medicine
- Hematology
- Neuroscience
Background:
- Erythropoiesis-stimulating agents (ESAs) have been researched for over 20 years in infants.
- Recent research explores darbepoetin (Darbe), a long-acting ESA, for erythropoietic and neuroprotective benefits.
Purpose of the Study:
- To review clinical trials of darbepoetin in term and preterm infants.
- To evaluate the erythropoietic and neuroprotective effects of darbepoetin.
Main Methods:
- Review of clinical trials involving darbepoetin in infant populations.
- Analysis of reported erythropoietic and neuroprotective outcomes.
Main Results:
- Darbepoetin demonstrated significant erythropoietic effects in infants.
- Clinical trials reported notable neuroprotective effects associated with darbepoetin use.
- ESAs show potential in reducing or eliminating the need for blood transfusions.
Conclusions:
- ESAs, including darbepoetin, hold significant promise for treating preterm and term infants.
- These agents can decrease transfusion requirements and offer protection against brain injury.
Keywords:
AnemiaDarbepoetinErythropoiesis-stimulating agentsNeurodevelopmentNeuroprotectionTransfusionsMore Related Videos
Related Concept Videos
01:29Drug Dosing: Infants and Children
804
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
804
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
484
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
484
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
378
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
378
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
762
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
762
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
341
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
341
01:27Parentral Nutrition: Centeral and Peripheral Parental Nutrition
1.6K
Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
1.6K